Article

Mmarketwatch.com on 2018-04-20 17:59

Ahead of earnings, Biogen’s Ionis deal perplexes

Biogen just announced a $1 billion deal, but it may not be enough to make investors happy.

Europe

Related news

MBiogen’s stock blasts off after surprise reversal on Alzheimer’s drug, earnings beat marketwatch.com
New York
BBiogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.3 min read barrons.com
Ionis and Biogen’s Spinraza Drug Wins FDA Approval wsj.com
MIonis Pharmaceuticals' stock soars as Biogen collaboration deal includes $1 billion payment marketwatch.com
TAnalyst overhauls S&P 500 target ahead of earnings season thestreet.com
Wall Street , Europe
Ionis Pharmaceuticals: Q2 Earnings Snapshot kentucky.com
Wall Street , Carlsbad
Ionis Pharmaceuticals: Q1 Earnings Snapshot thenewstribune.com
Wall Street , Carlsbad
MSalesforce earnings may be subdued ahead of big Dreamforce party marketwatch.com
Europe , San Francisco
U.S. futures point lower ahead of inflation data, earnings staradvertiser.com
Stockholm , South East , New Zealand , India , Sydney
Ionis Pharmaceuticals: Q3 Earnings Snapshot thenewstribune.com
Wall Street , Carlsbad
Ionis Pharmaceuticals: Q4 Earnings Snapshot kansascity.com
Wall Street , Carlsbad
Tesla cuts U.S. prices again ahead of 1Q earnings release staradvertiser.com
Rio de Janeiro , China , Amitsoq , Singapore , Israel